News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Boston Biotech Albireo (ALBO) Goes Public In Unusual Fashion



11/4/2016 7:17:36 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Boston biotech Albireo Pharma Inc. went public Thursday through a reverse merger in which it acquired the stock listing of a Connecticut company, in a deal that will leave Albireo with about $30 million to develop a treatment for a pediatric liver disease.

Albireo, which in 2008 was spun out of British drug giant AstraZeneca PLC, will begin trading on the Nasdaq stock exchange Friday morning under the stock ticker ALBO.

The stock swap with Danbury-based Biodel Inc. gave Albireo a relatively cheap way to access the public markets rather than complete an initial public offering, a spokesman said.

Read at Boston Globe


comments powered by Disqus
Albireo
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES